drugset / Trial / NCT00484237

A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis

NCT00484237

Phase 3 Completed 80 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the safety and efficacy for two regimens of etanercept in patients with rheumatoid arthritis (RA). The two regimens to be compared are a 25mg twice weekly regimen and a 50mg once weekly regimen.

Timeline

Start
2007-04
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 10 mg
Subject Etanercept Protein / enzyme biologic 25 mg
Subject Etanercept Protein / enzyme biologic 50 mg

Indications